Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adagene (Suzhou) Limited
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with advanced solid tumors or relapses/refractory non-Hodgkin's lymphoma confirmed by histology or cytology
Has at least one measurable lesion (solid tumor according to RECIST v1.1 criteria, non-Hodgkin's lymphoma according to Lugnao criteria)
ECOG score of 0 or 1;
Expected survival time ≥ 3 months (at the discretion of the investigator);
Adequate organ and bone marrow function;
Voluntarily sign the informed consent form;
You may not be if
Has central nervous system primary malignant tumor, active epileptic seizure, spinal cord compression or carcinomatous meningitis
The previous anti-tumor treatment has not passed the prescribed washout period
HIV antibody is positive, or with other acquired/congenital immunodeficiency disease, or with history of organ transplantation;
Active hepatitis B or hepatitis C virus (HCV) antibody was positive;
Patients who are pregnant or lactating;
Known or suspected hypersensitivity to the study drug or its pharmaceutical excipients (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol, polysorbate, arginine, succinic acid);
Any active autoimmune disease, or known history of autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive medications (other than controlled thyroid disease with alternative therapy/non-immunosuppressive therapy);
Participation in another therapeutic or interventional clinical study in the meantime;
Other circumstances where the investigator considers it is not appropriate to participate in the study.
Clareo Health | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
